Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Adapted Chemoradiotherapy and ASCT for Relapsed/Refractory Hodgkin's Lymphoma
NCT00255723Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2004
- Primary completion
- Jul 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of carboplatin, etoposide and ifosfamide in Hodgkin lymphoma (HL) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Objective Response at 3 years. Started Apr 2004; status: completed.
02
Drugs
carboplatinetoposideifosfamide
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00255723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255723.